The Wellcome Trust Sanger Institute Continues Scale Up with Order for 11 Additional Illumina, Inc. Genome Analyzers

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced that the Wellcome Trust Sanger Institute has purchased 11 additional Genome Analyzers, increasing the organization’s total number of the Illumina sequencing platform to 37. The continued scale up on the Genome Analyzer will support the Sanger Institute’s many initiatives, such as its contribution to the 1000 Genome Project, which requires economical, accurate, and rapid sequence generation.

Back to news